Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Review Article
Authors: Jin, Nanxianga; * | Babiloni, Claudiob; c | Drinkenburg, Wilhelmus H.d; e | Hajós, Mihályf; g | Nygaard, Haakon B.h | Tanila, Heikkia
Affiliations: [a] A. I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland | [b] Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, Rome, Italy | [c] Hospital San Raffaele Cassino, Cassino (FR), Italy | [d] Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium | [e] Groningen Institute for Evolutionary Life Sciences, University of Groningen, The Netherlands | [f] Cognito Therapeutics, Cambridge, MA, USA | [g] Yale School of Medicine, Yale University, New Haven, CT, USA | [h] Division of Neurology and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada
Correspondence: [*] Correspondence to: Nanxiang Jin, PhD, A. I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland. Tel.: +358 46 9435132; E-mail: [email protected].
Abstract: Recent evidence suggests that about 30%of patients with mild to moderate Alzheimer’s disease (AD) without a known diagnosis of epilepsy may display epileptiform spikes during electroencephalographic (EEG) recordings. These abnormal discharges occur predominantly during sleep and may be associated with accelerated disease progression. Subclinical spikes may represent a relevant target for clinical drug interventions, and there is a clear unmet need for preclinical testing of novel disease modifying agents in suitable animal models. Transgenic rodent models of AD pathology exhibit various forms of epileptiform EEG activity related to the abnormal levels of amyloid species in the brain. Among them, large-amplitude cortical and hippocampal EEG spikes in mouse and rat AD models may be reminiscent of the subclinical epileptiform EEG spikes recorded in some AD patients. This article reports the recommendations of a multidisciplinary panel of experts on optimal EEG markers and experimental designs to measure and report epileptiform activities and their response to symptomatic and disease-modifying drugs in transgenic AD model rodents. These recommendations may harmonize future preclinical EEG studies in the drug discovery research and may increase the comparability of experimental outcomes and their translational clinical value.
Keywords: Drug, EEG, epilepsy, epileptiform, mouse, rat, transgenic
DOI: 10.3233/JAD-210209
Journal: Journal of Alzheimer's Disease, vol. 88, no. 3, pp. 849-865, 2022
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]